Has There Been A Sea Change In Trial Diversity Efforts?
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
You may also be interested in...
Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.